Winton Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-366
| Closed | -$337K | – | 1358 |
|
|
2026
Q1 | $337K | Sell |
366
-12,989
| -97% | -$13.2M | 0.01% | 828 |
|
|
2025
Q4 | $14.4M | Buy |
13,355
+10,655
| +395% | +$10.2M | 0.5% | 39 |
|
|
2025
Q3 | $2.06M | Buy |
+2,700
| New | +$2.01M | 0.08% | 273 |
|
|
2025
Q2 | – | Sell |
-2,698
| Closed | -$2.23M | – | 917 |
|
|
2025
Q1 | $2.23M | Sell |
2,698
-1,550
| -36% | -$1.29M | 0.14% | 171 |
|
|
2024
Q4 | $3.28M | Buy |
4,248
+3,892
| +1,093% | +$3.22M | 0.22% | 120 |
|
|
2024
Q3 | $315K | Sell |
356
-3,045
| -90% | -$2.74M | 0.02% | 503 |
|
|
2024
Q2 | $3.08M | Buy |
+3,401
| New | +$2.72M | 0.21% | 96 |
|
|
2023
Q4 | – | Sell |
-5,604
| Closed | -$3.01M | – | 808 |
|
|
2023
Q3 | $3.01M | Sell |
5,604
-3,545
| -39% | -$1.83M | 0.25% | 76 |
|
|
2023
Q2 | $4.29M | Sell |
9,149
-4,384
| -32% | -$1.84M | 0.36% | 53 |
|
|
2023
Q1 | $4.65M | Buy |
13,533
+5,094
| +60% | +$1.72M | 0.28% | 51 |
|
|
2022
Q4 | $3.09M | Buy |
+8,439
| New | +$2.99M | 0.2% | 103 |
|
|
2022
Q3 | – | Sell |
-5,913
| Closed | -$1.92M | – | 1030 |
|
|
2022
Q2 | $1.92M | Sell |
5,913
-3,936
| -40% | -$1.18M | 0.1% | 277 |
|
|
2022
Q1 | $2.82M | Buy |
9,849
+2,682
| +37% | +$690K | 0.15% | 157 |
|
|
2021
Q4 | $1.98M | Buy |
7,167
+2,429
| +51% | +$616K | 0.12% | 229 |
|
|
2021
Q3 | $1.09M | Buy |
+4,738
| New | +$1.17M | 0.06% | 456 |
|
|
2021
Q2 | – | Sell |
-3,723
| Closed | -$696K | – | 1469 |
|
|
2021
Q1 | $696K | Buy |
+3,723
| New | +$728K | 0.04% | 687 |
|
|
2020
Q3 | – | Sell |
-1,280
| Closed | -$210K | – | 1546 |
|
|
2020
Q2 | $210K | Buy |
+1,280
| New | +$196K | 0.01% | 1351 |
|
|
2019
Q3 | – | Sell |
-5,191
| Closed | -$575K | – | 1615 |
|
|
2019
Q2 | $575K | Sell |
5,191
-437
| -8% | -$51.5K | 0.01% | 616 |
|
|
2019
Q1 | $730K | Sell |
5,628
-46,247
| -89% | -$5.62M | 0.01% | 441 |
|
|
2018
Q4 | $6M | Buy |
+51,875
| New | +$5.79M | 0.13% | 254 |
|
|
2018
Q3 | – | Sell |
-3,276
| Closed | -$280K | – | 1082 |
|
|
2018
Q2 | $280K | Sell |
3,276
-4,505
| -58% | -$370K | 0.01% | 857 |
|
|
2018
Q1 | $602K | Buy |
7,781
+978
| +14% | +$78.7K | 0.02% | 690 |
|
|
2017
Q4 | $575K | Sell |
6,803
-5,832
| -46% | -$496K | 0.02% | 461 |
|
|
2017
Q3 | $1.08M | Sell |
12,635
-122
| -1% | -$10K | 0.03% | 401 |
|
|
2017
Q2 | $1.05M | Buy |
+12,757
| New | +$1.04M | 0.03% | 343 |
|
|
2016
Q4 | – | Sell |
-4,026
| Closed | -$323K | – | 473 |
|
|
2016
Q3 | $323K | Sell |
4,026
-166,224
| -98% | -$13.3M | 0.01% | 364 |
|
|
2016
Q2 | $13.4M | Sell |
170,250
-73,198
| -30% | -$5.51M | 0.22% | 162 |
|
|
2016
Q1 | $17.5M | Buy |
243,448
+89,637
| +58% | +$6.78M | 0.19% | 190 |
|
|
2015
Q4 | $13M | Sell |
153,811
-111,859
| -42% | -$9.28M | 0.12% | 228 |
|
|
2015
Q3 | $22.2M | Buy |
265,670
+18,731
| +8% | +$1.58M | 0.18% | 219 |
|
|
2015
Q2 | $20.6M | Sell |
246,939
-217,472
| -47% | -$16.6M | 0.19% | 193 |
|
|
2015
Q1 | $33.7M | Buy |
464,411
+86,134
| +23% | +$6.13M | 0.27% | 153 |
|
|
2014
Q4 | $26.1M | Sell |
378,277
-602,334
| -61% | -$40.7M | 0.32% | 112 |
|
|
2014
Q3 | $63.6M | Sell |
980,611
-253,014
| -21% | -$16M | 0.45% | 53 |
|
|
2014
Q2 | $76.7M | Buy |
+1,233,625
| New | +$73.6M | 0.52% | 30 |
|
Other funds holding LLY
N
Winton Group's LLY Position: Q2 2026 in Review
Winton Group sold out of Eli Lilly (LLY) in Q2 2026, closing a stake of 366 shares — an estimated $337K sold.
Winton Group first reported a position in LLY in Q2 2014 and held it in 35 quarters. The position peaked at $76.7M in Q2 2014. 3,468 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Winton Group reported no remaining Eli Lilly position as of Q2 2026 after selling out during the quarter.
- Winton Group sold 366 Eli Lilly shares in Q2 2026, an estimated $337K.
- Winton Group first reported a position in Eli Lilly in Q2 2014 and held it in 35 quarters.
- Winton Group's Eli Lilly position peaked at $76.7M in Q2 2014.
- 3,468 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.